SAN ANTONIO, Texas, Nov. 17 /PRNewswire/ -- OsteoBiologics, Inc. (OBI), an innovator in tissue repair technologies, announced today the clearance by the Food and Drug Administration (FDA) of the OsteoChondral Transplant (OCT) Comprehensive System Instruments for the treatment of osteochondral (cartilage) defects. The OCT Comprehensive System consists of both graft and defect preparation instruments which are indicated for use in open and arthroscopic osteochondral grafting in the treatment of defects in the knee and ankle. Currently, the defect preparation instruments are commercially available as the TruKor(R) and TruKor(R) Plus Instruments.
Fred Dinger, President and CEO of OBI, commented, “The FDA clearance of our OCT System represents a milestone for the company as this is the first OBI product specifically indicated in the United States for the treatment of osteochondral/cartilage defects. We recognize the importance of instrumentation to the success of surgical procedures and are committed to providing comprehensive instrument systems that meet patient needs and surgeon requirements.” The OCT System complements the company’s PolyGraft(R) family of bone repair scaffolds, which includes the TruFit(R), TruGraft(TM), TruBlock(TM) and other implants.
In February 2005, OBI received the CE Mark (European approval) for scaffolds and instruments for cartilage and bone repair. “Scaffolds represent the next generation of minimally invasive and biorestorative treatments for osteochondral/cartilage defects,” said David Caborn, M.D., Chief Division of Sports Medicine, Jewish Hospital, Louisville, KY.
About OsteoBiologics, Inc.
OBI, located in San Antonio, Texas, is a private company that develops, manufactures and markets bioabsorbable polymeric scaffolds, films, and related instrumentation for the repair and replacement of bone, soft tissue and articular cartilage. Its products are based on proprietary and patented technologies covered by U.S. and foreign patents. The PolyGraft(TM) product and related scaffold formulations are protected under U.S. Patent Nos. 5,716,413, 6,511,511 and other patents pending.
The Company is focused on commercializing and further developing its platform technologies in arthroscopy and sports medicine. Additionally, OBI is actively forming strategic alliances with companies serving other areas of medicine such as spine, trauma, general orthopedics, extremities, and wound care to leverage its technologies into those markets.
Certain statements made in this press release are forward looking statements as such term is defined in the Private Securities litigation Reform Act of 1995.
For more information, please contact: Daniel Lee, Director of Marketing OsteoBiologics, Inc. P: (210) 690-2131 daniel.lee@obi.com
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20031002/OBILOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk,photodesk@prnewswire.comOsteoBiologics, Inc.
CONTACT: Daniel Lee, Director of Marketing of OsteoBiologics, Inc.,+1-210-690-2131, or daniel.lee@obi.com
Web site: http://www.obi.com/
